Jonathan Chang
Stock Analyst at Leerink Partners
(0.63)
# 4,119
Out of 5,111 analysts
81
Total ratings
30.67%
Success rate
-19.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Upgrades: Outperform | $3 → $13 | $8.90 | +46.07% | 11 | Oct 20, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $17.33 | +332.78% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $31.82 | -15.15% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $33.78 | +119.06% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $22.13 | -50.29% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $13.12 | +288.72% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $7.19 | +943.12% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $6.68 | +648.50% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $79.02 | -62.03% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.61 | +645.34% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $325 → $350 | $29.04 | +1,105.23% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $10.45 | +148.80% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $10.34 | +170.92% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $14.92 | +255.23% | 7 | Aug 5, 2021 |
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $3 → $13
Current: $8.90
Upside: +46.07%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $17.33
Upside: +332.78%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $31.82
Upside: -15.15%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $33.78
Upside: +119.06%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $22.13
Upside: -50.29%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $13.12
Upside: +288.72%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $7.19
Upside: +943.12%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $6.68
Upside: +648.50%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $79.02
Upside: -62.03%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.61
Upside: +645.34%
Aug 9, 2022
Maintains: Outperform
Price Target: $325 → $350
Current: $29.04
Upside: +1,105.23%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $10.45
Upside: +148.80%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $10.34
Upside: +170.92%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $14.92
Upside: +255.23%